MENU
SBIO
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

SBIO stock forecast, quote, news & analysis

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index... Show more

Category: #Health
SBIO
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for SBIO with price predictions
Sep 29, 2026

SBIO's Indicator enters downward trend

The Aroon Indicator for SBIO entered a downward trend on September 29, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 207 similar instances where the Aroon Indicator formed such a pattern. In 186 of the 207 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SBIO as a result. In 76 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for SBIO turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 45 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

SBIO moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SBIO crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in 285 of 321 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

SBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF (SBIO) ETF is 2.19B. The market cap for tickers in the group ranges from 69.23M to 6.17B. CGON holds the highest valuation in this group at 6.17B. The lowest valued company is TENX at 69.23M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF (SBIO) ETF was -9%. For the same ETF, the average monthly price growth was -14%, and the average quarterly price growth was 8%. NAMS experienced the highest price growth at 2%, while ACAD experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF (SBIO) ETF was -16%. For the same stocks of the ETF, the average monthly volume growth was 37% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 77
Price Growth Rating: 57
SMR Rating: 93
Profit Risk Rating: 86
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
SBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
ALPS ETFPO Box 328Denver
Phone
855.724.0450
Web
www.alpsfunds.com